The Canadian Multiple Sclerosis Working Group has updated its treatment optimization
recommendations (TORs) on the optimal use of disease-modifying therapies for patients …

With evolving diagnostic criteria and the advent of new oral and parenteral therapies for MS,
most current diagnostic and treatment algorithms need revision and updating. The diagnosis …

Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by
inflammation and demyelination for which there is currently no cure; therefore, the aim of …

Background SARS-CoV-2 viral infection causes COVID-19 that can result in severe acute
respiratory distress syndrome (ARDS), which can cause significant mortality, leading to …

Monoclonal antibodies have become a mainstay in the treatment of patients with relapsing
multiple sclerosis (RMS) and provide some benefit to patients with primary progressive MS …

The risk of infection associated with immunomodulatory or immunosuppressive disease-
modifying drugs (DMDs) in patients with multiple sclerosis (MS) has been increasingly …

Introduction: Idiosyncratic drug-induced neutropenia and agranulocytosis is seldom
discussed in the literature, especially for new drugs such as biotherapies outside the context …

Background Autologous haematopoietic stem cell transplantation (AHSCT) is a highly
effective treatment for multiple sclerosis (MS). The impact of previous long-lasting disease …

The majority of disease-modifying drugs (DMDs) available for the management of active
relapsing–remitting multiple sclerosis (RMS) depend on continuous drug intake for …

Purpose The aim of this study was to review the scientific evidence and describe the ocular
treatment-emergent adverse events (TEAEs) related to pharmacological treatment in …